GSK to Cut Costs with £1.9bn Programme
Pharmaceutical giant announces significant investment in UK life sciences alongside R&D site closures and relocations.
Trust 42Craft 55Hype 30How this was reported ▾
Single named source (GSK CEO) with no independent verification or local detail.
How well corroborated and evidenced the reporting is. Higher is better.
Lacks affected voices, local impact, or next steps for residents.
Context, balance and separation of fact from comment. Higher is better.
Headline overstates job cuts; body provides context but no local angle.
How far presentation runs ahead of substance. Lower is better.
1 source assessed · methodology
Pharmaceuticals company GSK is launching a £1.9bn cost-cutting programme, with plans to invest £400m in UK life sciences over the next three years. This initiative includes the relocation of over 1,000 scientists to a new research and development site in Cambridge. The company also announced the closure of its R&D facility in Stevenage, Hertfordshire, by 2029.
Strategic Investment and Relocation
The new Cambridge site, situated on the biomedical campus, will span 300,000 sq ft and is designed to support research in areas such as oncology, respiratory conditions, hepatology, vaccines, and HIV. GSK stated that this move will integrate the company further into a leading global knowledge centre and enhance access to a network of biomedical research, patient care, and academic institutions. The company's investment has been welcomed by government officials as a boost for homegrown innovation and expertise.
Sunseeker Holiday Homes enters administration
The Hull-based manufacturer, founded in 2019, has appointed administrators, putting 76 jobs at risk.
As part of the changes, GSK will also upgrade its R&D laboratories in Ware and transfer some employees there. The company aims to accelerate drug development, with a plan to double the number of phase 3 trials launched to 20. These large-scale studies are crucial for testing the efficacy of new treatments against existing ones or placebos.
Cost Savings and Future Plans
The £1.9bn cost-saving programme is targeted to achieve annual savings by 2029. According to Luke Miels, the GSK chief executive, approximately 45% of these savings are expected to come from efficiencies in support services, procurement, and process simplification. A further 40% will be generated by reallocating resources from established treatments to focus on new drug development. The exact number of global redundancies resulting from this programme has not been disclosed.
Enfield Town Liveable Neighbourhood scheme paused pending review
Transport for London funding for next phase is on hold as council re-evaluates project elements.
This announcement follows a period of strategic review under Mr Miels, who took over as chief executive earlier this year. The company's shares saw a 6% increase on the London stock market following the announcement. The closure of the Stevenage site comes five years after GSK had announced plans to spend £400m on extending that campus.
Questions this report answers
+How much is GSK investing in UK life sciences?
GSK is investing £400 million in UK life sciences over the next three years. This funding will support research and development, including the new Cambridge site, and is part of a broader £1.9 billion cost-cutting programme aimed at boosting innovation and efficiency.
+Where will the scientists be moving to?
Over 1,000 scientists will relocate to a new research and development site in Cambridge. The 300,000 sq ft facility will focus on areas like oncology, vaccines, and HIV, integrating GSK into a leading global biomedical research hub.
+What will happen to the Stevenage site?
GSK plans to close its R&D facility in Stevenage, Hertfordshire, by 2029. This follows a strategic review and is part of the company’s cost-cutting programme, which aims to streamline operations and reallocate resources to new drug development.
+How will GSK achieve its cost savings?
GSK expects to save £1.9 billion by 2029, with 45% coming from efficiencies in support services and procurement, and 40% from reallocating resources to new drug development. The exact number of redundancies has not been disclosed.
Barnet Press News Desk
This article was written at the Barnet Press news desk from the reporting of the outlets listed below it. Drafting is done by a language model under human editorial supervision — there is no reporter behind this byline, and we would rather say so than invent one.
How stories are produced and scoredWho runs Barnet PressCorrections
Barnet conditions
Loading live conditions…
More Coverage in World
Sunseeker Holiday Homes enters administration
Enfield Town Liveable Neighbourhood scheme paused pending review
